ArticleJournal of cachexia, sarcopenia and muscle2014
Are we closer to having drugs to treat muscle wasting disease?
Article in Journal of cachexia, sarcopenia and muscle, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 72 citations in OpenAlex.
- Recent Articles-Skeletal Muscle and Other Topics in Diabetes.Journal of diabetes · 2025Article
- Are we giving too much weight to lean mass loss?Molecular metabolism · 2025Review
- Skeletal muscle immobilisation-induced atrophy: mechanistic insights from human studies.Clinical science (London, England : 1979) · 2024Review
- Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-α blocker.Journal of clinical biochemistry and nutrition · 2022Article
- Physiologic and molecular characterization of a novel murine model of metastatic head and neck cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2021Article
- Formononetin ameliorates muscle atrophy by regulating myostatin-mediated PI3K/Akt/FoxO3a pathway and satellite cell function in chronic kidney disease.Journal of cellular and molecular medicine · 2021Article
- Metastasis and cachexia: alongside in clinics, but not so in animal models.Journal of cachexia, sarcopenia and muscle · 2019Review
- Promoting mobility and healthy aging in men: a narrative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Review
- Sarcopenia: A Time for Action. An SCWD Position Paper.Journal of cachexia, sarcopenia and muscle · 2019Review
- Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia.Journal of clinical biochemistry and nutrition · 2019Article
- Review
- Multimodal Intervention to Improve Functional Status in Hypertensive Older Adults: A Pilot Randomized Controlled Trial.Journal of clinical medicine · 2019Article
- Observational
- The Skeletal Muscle as an Active Player Against Cancer Cachexia.Frontiers in physiology · 2019Review
- Anorexia of Aging - An Updated Short Review.The journal of nutrition, health & aging · 2019Review
- The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2018Article
- Current Status of Sarcopenia in Korea: A Focus on Korean Geripausal Women.Annals of geriatric medicine and research · 2018Review
- Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.Journal of cachexia, sarcopenia and muscle · 2017Article
- Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia.Journal of cachexia, sarcopenia and muscle · 2017Article
- Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.Journal of cachexia, sarcopenia and muscle · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.